Women have contributed greatly to the psychedelics industry, accomplishing incredible research and work in the field, despite being maligned in serious ways for just being involved. Given that International Women’s Month has just ended, the timing seems ideal to shine a spotlight on women pioneers of psychedelics, along with a focus on what exactly held them back.
Women have had to jump through hurdles that did not exist for their male counterparts as well as bypass barriers in various industries and fields, including the field of psychedelic research. Knowledge of history or sometimes just personal experience has shown that the presence of women has been discouraged in education, career options, and other sectors that were dominated by men. While it may not seem like a big deal to some, gender discrimination has hindered a lot of progress from being made.
For instance, when researchers looked into LSD as a possible treatment for alcoholism, gender segregation still barred women from going to pubs, even in the ‘70s, which left men to develop alcoholism treatments. This translated into men also owning alcoholism LSD-assisted therapy space.
In addition to this, women considering to be in their child-bearing years were excluded and discouraged from taking part in clinical trials, with researchers of the time fearing that their participation would risk the reproductive abilities of their bodies.
The scientists’ reasons obviously hint at the societal misconception that saw women as lesser beings that weren’t smart enough for life sciences. You may have heard the phrase, “a woman’s place is in the kitchen,” which discredits women’s abilities and ties their purpose to the domestic lifestyle, which generally involves producing offspring and cleaning.
Furthermore, many women who persevered and made their mark in research sectors still had to work behind the scenes or co-author their findings with men, sacrificing credit that was deserved and hiding their names in order to enhance the study of psychedelic substances.
With regard to the benefits of psilocybin, it may not be common knowledge that much of what we know about psilocybin mushrooms came Maria Sabina.
In 1955, Maria Sabina shared her knowledge of psilocybin mushrooms with Robert Gordon Wasson and Valentina Wasson. The two researchers presented this research in 1957 through an interview entitled “I Ate the Scared Mushrooms” with Tina’s This Week and a photo essay entitled “Seeking the Magic Mushrooms,” which was published in Life magazine.
Sabina’s revelation brought psilocin and psilocybin into the spotlight, which led Albert Hoffman, who is known as the father of LSD and its discoverer, to focus his attention to psychedelic substances for further research. However, despite the use of a pseudonym to protect Sabina’s identity, she was soon found out; the rest of her story is tragic.
Thanks to the pioneering work done by different people and entities decades ago, many companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are advancing psychedelic-medicine formulation programs with an aim of finding remedies to the worsening mental health conditions that seem to be unresponsive to the existing medications.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.